Articles: function.
-
Cardiovascular Disease PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The risk of stroke associated to the various means of cardiac stimulation is still limited and offers only tendencies. It is only known that patients with sinus node dysfunction are in risk of stroke and suggest that ventricular demand pacemakers do not offer protection against this risk. ⋯ The following authors have nothing to disclose: Elieusa Sampaio, Roque Aras Júnior, José Alberto da Matta, Cristiano Macedo, Márcia Maria Oliveira, Ubiratan dos Santos Júnior, Sérgio CâmaraNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Patients with severe COPD experience marked deterioration in lung function and breathlessness compared to patients with mild-to-moderate COPD. We report improvement of dyspnea and lung function in patients with severe COPD in the BLAZE study with QVA149, a dual bronchodilator combining the long-acting β2-agonist (LABA) indacaterol and the long-acting muscarinic antagonist (LAMA) glycopyrronium (NVA237), versus placebo and tiotropium. ⋯ Anthony D'Urzo: Consultant fee, speaker bureau, advisory committee, etc.: Novartis, AstraZeneca, Forest Laboratories, Pfizer, Schering Plough, Grant monies (from industry related sources): GSK, Schering Plough, Methapharma, AstraZeneca, Merck Canada, Forest Laboratories, Novartis Donald Mahler: Grant monies (from industry related sources): Boehringer Ingelheim, Novartis, and Sunovion, Consultant fee, speaker bureau, advisory committee, etc.: GlaxoSmithKline, Novartis, and Sunovion, and have served on Advisory Boards for Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pearl, and Sunovion Tracy White: Employee: Novartis Pharmaceuticals Corporation Vijay Alagappan: Employee: Novartis Pharmaceuticals Corporation Hungta Chen: Employee: Novartis Pharmaceuticals Corporation Karoly Kulich: Employee: Novartis Pharma AG Nicola Gallagher: Employee: Novartis Horsham Research Centre Donald Banerji: Employee: Novartis Pharmaceuticals Corporation The following authors have nothing to disclose: Heinrich WorthClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The IGNITE program investigated the efficacy and safety of dual bronchodilation with once-daily QVA149 [fixed-dose combination of indacaterol (long-acting β2-agonist) and glycopyrronium (long-acting muscarinic antagonist)] for the treatment of patients with moderate-to-severe COPD. ⋯ Karen Mezzi: Employee: Novartis Employee Mark Fedele: Employee: Novartis Employee Hungta Chen: Employee: Novartis Employee Donald Banerji: Employee: Novartis EmployeeClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
Comorbidities of OSA PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The cardiovascular complications(CVC) are the important causes of mortality/morbidity in OSAS. Hypoxia, vascular endothelial dysfunction and hypercoagulability are some of the pathophysiological mechanisms. In presence of hypoxia, hematocrit increases to maintain constant delivery of oxygen to the tissue. Hyperviscosity from increased hematocrit is one of the stimuli for atherosclerotic process. Mean platelet volume(MPV) is an indicator of platelet activation and was found to be an indicator for atherosclerosis. We investigated correlation between the hematocrit and MPV levels with the severity and response of OSAS to the CPAP therapy. ⋯ The following authors have nothing to disclose: Gülcan Çetin, Elif Kupeli, Serife Savas Bozbas, Füsun Öner EyüboğluNo Product/Research Disclosure Information.
-
Transplantation PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: We retrospectively reviewed the complications occurred in the immediate postoperatory (IPO) of lung transplantation (LTx). ⋯ Jordi Rello: Grant monies (from sources other than industry): Study financed partly with Spanish Government Grant FIS PI11/01122 The following authors have nothing to disclose: Jordi Riera, Berta Caralt, Salvador Augustin, Joan Ramon Masclans, Merce Canela, Antonio RomanNo Product/Research Disclosure Information.